MAR 1, 5 200

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

\$ 1,436,502

DE 249 241

Date Considered

6B

B5

B6

-21

21

Examiner

Compl	ete if Known	
Application Number	10/732,838	
Filing Date	December 10, 2003	
First Name Inventor	Chen	
Group Art Unit	1624	
Examiner Name	TUCKER, Z.	
Attorney Docket Number	21101 HS2	

> .	3		T T			Examiner Name	TUCKER		
REDENA	Sheet	1	of	1		Attorney Docket Number	21101	US2	
TRANSMA	U.S. PATENT DOCUMENTS							·	
	Examine Initials'	r Cite	U. Numbe		Kind Code ³ (if known)	Name of Patentee or Appl Cited Document	icant of	Date of Publication Cited documer MM-DD-YY	nt
	Z٢	A1	5,169	9,951		Sutter, et al.		12-08-1992	
	21	A2	5,113	3,013		Powell, et al.		05-12-1992	
i	子	A3	3,431	,301		Focella, et al.		03-04-1969	
	21	A4	3,776	5,917		Mann, et al.		12-04-1973	
	21	A5	5,556	5,859		Johnson		09-17-1996	
1	红	A6	6,486	5,184		Kester, et al.		11-26-2002	
•	2+	· A7	6,610),846		Bizzarro, et al.		08-26-2003	
	2	A8	6,528	3,543		Bizzarro, et al.		03-04-2003	
	27	A9	6,320),050		Bizzarro, et al.		11-20-2001	
	27	A10	6,353	3,111		Corbett, et al.		03-05-2002	
	25	A11	6,489	,485		Bizzarro, et al.		12-03-2002	
	21	A12	6,369	,232		Sidduri		04-09-2002	
•	27	A13	6,388	3,088		Sidduri		05-14-2002	
	27	A14	6,441	,180		Sidduri		08-27-2002	
3.	27	A15	6,384	,220		Corbett, et al.		05-07-2002	
	ZT	A16	6,388	3,071		Mahaney		05-14-2002	
,	21	A17	6,441	,184		Corbett, et al.		08-27-2002	
	.75.	A18	6,433	3,188		Corbett, et al.		08-13-2002	
	2+	A19	6,545	,155		Corbett, et al.		08-08-2003	
	2	A20	6,448			Corbett, et al.		09-10-2002	
{						TENT DOCUMENTS			
	Examiner Initials'	Cite	Foreign Office ³	Number	Kind Code	Name of Patentee or Applicant of Cited Docum		e of Publication of Cited Document MM-DD-YYYY	T
	21	B1	EP 50	66 138	.,	Hodogaya Chemical Co., Ltd.	10-	20-1993	
	21	B2	WO	00/26202		Pharmacia & Upjohn S.P.A.	n 05-	11-2000	
\vee	红	B3		00/58293		F. Hoffmann-La Roche AG		-05-2000	
	21	B4	WO	02/08209		F. Hoffmann-La Roche AG	01-	31-2002	

Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

et al.

Robert G.W. Spickett,

Farbenfabriken

05-19-1976

07-13-1912

22 JUNE 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation it not in conformance and not consumered. Initial from with next communication to applicant.

*Unique citation designation number. *See strached Kinds of U.S. Patent Documents, *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

/011	£ 7			for form 1449A/PTO	Con	plete if Known
/	S.	FORMA	TION	DISCLOSURE	Application Number	10/732,838
MAR 1	5 2004 S	ATEME	NT B	Y APPLICANT	Filing Date	December 10, 2003
B MAN .	2004	ď			First Name Inventor	Chen
H	Á	(Use seve	ral shee	ets if necessary)	Group Art Unit	1624
W.	RANTHER				Examiner Name	TUCKER, Z.
	Sheet	2	Of	2	Attorney Docket Number	21101 US2

NON PATENT LITERATURE DOCUMENTS

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, scrial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²				
21	C1	COLOWICK, S.P., The Enzymes, Vol. 9 (P. Boyer, ed.) Academic					
		Press, New York, NY, pg. 1-48 (1973)	╁				
ZT	C2	CHIPKIN, et. al., in Joslin's Diabetes (C.R. Kahn and G.C. Wier, eds.), Lea and Febiger, Philadelphia, PA, pg. 97-115 (1994)					
25	C3	PRINTZ, et. al., Ann. Rev. Nutrition, Vol. 13 (R.E. Olson, D.M. Bier,					
		and D.B. McCormick, eds.) Annual Review Inc, Palo Alto, CA pp.					
		463-496 (1993)					
21	C4	MEGLASSON, et. al., Amer. J. Physiol., 246, E1-E13 (1984)	1				
21	C5	GRUPE, et. al., Cell 83, 69-78, (1995)					
ZT	C6	FERRE, et al., FASEB J., 10, 1213-1218 (1996)	Т				
ZT	C7	LIANG, et al., Biochem. J. 309, 167-173 (1995)					
25	C8	GLASER, et. al. New England J. Med. 338, 226-230 (1998)					
2T 2T 2T	, C9	RODIER, et. al., Acta Crystallogr., C46 (1990) pp. 154-156					
' स	C10	ROBERT, J. M. H., et. al., Eur J. Med. Chem. Vol. 29, (1994), pp. 841-854					
क	C11	SPICKETT, et. al., Eur. J. Med. ChemChimica Therapeutica, Vol.	╁				
		11(1), (1976), pp. 7-12	1				
25	C12	BHAT, A. R., et. al., J. Inst. Chemists (India), Vol. 61, 1989, pp. 134-136					
21	C13	SPIELMAN, M.A., et. al., J. Am. Chem. Soc., 70 (1948), pp. 4189-4191					
			+				
			İ				
*			+				
			†				
·			1				
-			+				
			F				
			-				
Examiner Signature	0	DATE CONSIDERED 22 JUNE 2005					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.

139699